ProMIS Neurosciences, Inc.
NASDAQ Capital MarketTotal Valuation
ProMIS Neurosciences, Inc. carries a market capitalization of 18.95M, placing it among publicly traded companies globally. Its enterprise value stands at -22.04M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 18.95M |
| Enterprise Value | -22.04M |
Share Statistics
ProMIS Neurosciences, Inc. currently has 8.97M shares outstanding.
| Shares Outstanding | 8.97M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.30 |
| P/TBV Ratio | 0.69 |
| P/FCF Ratio | -1.18 |
| P/OCF Ratio | -1.18 |
Financial Position
ProMIS Neurosciences, Inc. maintains a current ratio of 9.92, meaning it holds 9.9x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 9.92 |
| Quick Ratio | 9.69 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -100.21 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
ProMIS Neurosciences, Inc.'s stock has declined approximately -48.25% over the past 52 weeks. The 50-day moving average sits at 11.41, while the 200-day moving average is 11.95.
| Beta (5Y) | N/A |
| 52-Week Price Change | -48.25% |
| 50-Day Moving Average | 11.41 |
| 200-Day Moving Average | 11.95 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -41.35M, while operating income came in at -41.35M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -41.35M |
| Pretax Income | -40.62M |
| Net Income | -40.62M |
| EBITDA | -41.35M |
| EBIT | -41.35M |
| Earnings Per Share (EPS) | -12.34 |
Balance Sheet
Total book value stands at -138.65M, with working capital of 59.00M providing operational flexibility.
| Cash & Cash Equivalents | 63.85M |
| Total Debt | N/A |
| Net Debt | -63.81M |
| Equity (Book Value) | -138.65M |
| Book Value Per Share | -42.12 |
| Working Capital | 59.00M |
Cash Flow
ProMIS Neurosciences, Inc. produced -35.58M in operating cash flow over the past twelve months.
| Operating Cash Flow | -35.58M |
| Capital Expenditures | N/A |
| Free Cash Flow | -35.58M |
| FCF Per Share | -10.81 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -217.74 |
| FCF Yield | -85.10 |
Stock Splits
ProMIS Neurosciences, Inc.'s most recent stock split took place on November 28, 2025 with a 25:1 split ratio.
| Last Split Date | 11/28/2025 |
| Split Ratio | 25:1 |
Scores
ProMIS Neurosciences, Inc. posts an Altman Z-Score of -0.11, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -0.11 |